{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:17:44Z","timestamp":1790695064282,"version":"4.1.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MUR PNRR \u201cNational Center for Gene Therapy and Drugs based on RNA Technology","award":["CN00000041, CN3"],"award-info":[{"award-number":["CN00000041, CN3"]}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-acting drug delivery systems (LADDS) have emerged as an effective strategy to overcome the limitations of conventional oral and parenteral therapies, enabling sustained drug exposure, reduced dosing frequency, and improved patient compliance. To date, clinically approved long-acting injectables (LAIs) predominantly rely on chemical platforms, including biodegradable polymeric depots, lipid-based formulations, and crystalline nanosuspensions. Although these systems have demonstrated significant clinical success, their performance is largely dictated by formulation-dependent physicochemical mechanisms and is often associated with challenges such as local tissue reactions, formulation instability, and limited flexibility in controlling release kinetics. In recent years, biologically derived carriers have gained increasing attention as next-generation long-acting delivery systems. Among these, extracellular vesicles (EVs) represent a unique class of endogenous nanocarriers with intrinsic stability, low immunogenicity and biologically driven interactions with tissues and cells, thereby positioning them as promising candidates for sustained drug delivery applications. This review summarizes current LAI technologies, highlighting the strengths and limitations of established chemical LAIs, and critically examines the emerging potential of EV-based injectable systems. Particular emphasis is placed on engineering strategies that enable EVs to acquire depot-like behavior, including hydrogel-based formulations and microneedle platforms that extend local retention and modulate release kinetics while preserving EV bioactivity. Finally, key challenges related to manufacturing scalability, reproducibility, regulatory standardization, and clinical translation of EV-based LAIs are discussed. This review outlines the opportunities and remaining barriers for translating EVs into clinically viable long-acting drug delivery applications. Overall, these considerations provide a framework for advancing the rational design and clinical translation of EV\u2013based long-acting delivery platforms.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-026-02117-6","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:21:01Z","timestamp":1776021661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Redefining long-acting injectables: the emerging role of extracellular vesicles in sustained drug delivery"],"prefix":"10.1007","author":[{"given":"Sara","family":"Mathlouthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Szczepanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Malfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Kuryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"2117_CR1","unstructured":"Kim J, De Jesus O. Medication Routes of Administration, StatPearls. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568677\/. Accessed 24 Dec 2025."},{"key":"2117_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUDIS.2025.104447","volume":"30","author":"E Larra\u00f1eta","year":"2025","unstructured":"Larra\u00f1eta E, Dom\u00ednguez-Robles J. Long-acting drug delivery systems: current landscape and future prospects. Drug Discov Today. 2025;30:104447. https:\/\/doi.org\/10.1016\/J.DRUDIS.2025.104447.","journal-title":"Drug Discov Today"},{"key":"2117_CR3","doi-asserted-by":"publisher","unstructured":"Sreeraj VS, Shivakumar V, Rao NP, Venkatasubramanian G. Long-acting drug delivery systems for schizophrenia treatment. Elsevier; 2021.https:\/\/doi.org\/10.1016\/B978-0-12-821749-8.00009-4.","DOI":"10.1016\/B978-0-12-821749-8.00009-4"},{"key":"2117_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320. https:\/\/doi.org\/10.1023\/A:1016212804288.","journal-title":"Pharm Res"},{"key":"2117_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/S13311-017-0520-4","volume":"14","author":"AM Mehta","year":"2017","unstructured":"Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14:358. https:\/\/doi.org\/10.1007\/S13311-017-0520-4.","journal-title":"Neurotherapeutics"},{"key":"2117_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1208\/S12248-016-0025-9","volume":"19","author":"R Wang","year":"2017","unstructured":"Wang R, Conner DP, Li BV. Bioavailability and bioequivalence aspects of oral modified-release drug products. AAPS J. 2017;19:360\u20136. https:\/\/doi.org\/10.1208\/S12248-016-0025-9.","journal-title":"AAPS J"},{"key":"2117_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJANTIMICAG.2020.106220","author":"C Flexner","year":"2021","unstructured":"Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2020.106220.","journal-title":"Int J Antimicrob Agents"},{"key":"2117_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2023.114901","author":"R Sharma","year":"2023","unstructured":"Sharma R, Yadav S, Yadav V, Akhtar J, Katari O, Kuche K, et al. Recent advances in lipid-based long-acting injectable depot formulations. Adv Drug Deliv Rev. 2023. https:\/\/doi.org\/10.1016\/J.ADDR.2023.114901.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2021.113957","author":"H Abdelkader","year":"2021","unstructured":"Abdelkader H, Fathalla Z, Seyfoddin A, Farahani M, Thrimawithana T, Allahham A, et al. Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: inserts, patches, wafers, and implants. Adv Drug Deliv Rev. 2021. https:\/\/doi.org\/10.1016\/J.ADDR.2021.113957.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/17425247.2023.2175814","volume":"20","author":"T Hye","year":"2023","unstructured":"Hye T, Moinuddin SM, Sarkar T, Nguyen T, Saha D, Ahsan F. An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opin Drug Deliv. 2023;20:335. https:\/\/doi.org\/10.1080\/17425247.2023.2175814.","journal-title":"Expert Opin Drug Deliv"},{"key":"2117_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","volume":"8","author":"JM Kane","year":"1998","unstructured":"Kane JM, Aguglia E, Altamura AC, Gutierrez JLA, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 1998;8:55\u201366. https:\/\/doi.org\/10.1016\/S0924-977X(97)00045-X.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2117_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/POLYM3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377\u201397. https:\/\/doi.org\/10.3390\/POLYM3031377.","journal-title":"Polymers"},{"key":"2117_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/CRITREVTHERDRUGCARRIERSYST.V26.I6.10","volume":"26","author":"A Puri","year":"2009","unstructured":"Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523. https:\/\/doi.org\/10.1615\/CRITREVTHERDRUGCARRIERSYST.V26.I6.10.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2117_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2015.00286\/XML","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:163819. https:\/\/doi.org\/10.3389\/FPHAR.2015.00286\/XML.","journal-title":"Front Pharmacol"},{"key":"2117_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanz\u00e1-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4:198. https:\/\/doi.org\/10.1177\/2045125314540297.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2117_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/PHARMACEUTICS16010028","volume":"16","author":"M Markowicz-Piasecka","year":"2024","unstructured":"Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Ko\u0142odziejczyk M, Grzeli\u0144ska J, Fabija\u0144ska M, et al. Long-acting injectable antipsychotics\u2014a review on formulation and in vitro dissolution. Pharmaceutics. 2024;16:28. https:\/\/doi.org\/10.3390\/PHARMACEUTICS16010028.","journal-title":"Pharmaceutics"},{"key":"2117_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025649","volume":"36","author":"K Chaudhary","year":"2019","unstructured":"Chaudhary K, Patel MM, Mehta PJ. Long-acting injectables: current perspectives and future promise. Crit Rev Ther Drug Carrier Syst. 2019;36:137\u201381. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2018025649.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2117_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9798-5_1","volume":"2059","author":"KK Jain","year":"2020","unstructured":"Jain KK. An overview of drug delivery systems. Methods Mol Biol. 2020;2059:1\u201354. https:\/\/doi.org\/10.1007\/978-1-4939-9798-5_1.","journal-title":"Methods Mol Biol"},{"key":"2117_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17425247.2022.2105318","volume":"19","author":"A Gonella","year":"2022","unstructured":"Gonella A, Grizot S, Liu F, L\u00f3pez Noriega A, Richard J. Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules. Expert Opin Drug Deliv. 2022;19:927\u201344. https:\/\/doi.org\/10.1080\/17425247.2022.2105318.","journal-title":"Expert Opin Drug Deliv"},{"key":"2117_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/POLYM16192807","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yin Z, Xiang S, Yan H, Tian H. Degradation of polymer materials in the environment and its impact on the health of experimental animals: a review. Polymers. 2024;16:2807. https:\/\/doi.org\/10.3390\/POLYM16192807.","journal-title":"Polymers"},{"key":"2117_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/J.APMT.2024.102497","volume":"41","author":"Y Tao","year":"2024","unstructured":"Tao Y, Tan X, Zhang T. Enhancing biocompatibility and degradation control of biodegradable polymers through amino acid grafting: a study on 4arm-PLGA-amino acid copolymers. Appl Mater Today. 2024;41:102497. https:\/\/doi.org\/10.1016\/J.APMT.2024.102497.","journal-title":"Appl Mater Today"},{"key":"2117_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ADVS.202304632","volume":"10","author":"CV Maduka","year":"2023","unstructured":"Maduka CV, Alhaj M, Ural E, Habeeb OM, Kuhnert MM, Smith K, et al. Polylactide degradation activates immune cells by metabolic reprogramming. Adv Sci. 2023;10:2304632. https:\/\/doi.org\/10.1002\/ADVS.202304632.","journal-title":"Adv Sci"},{"key":"2117_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/TEN.2006.12.301","volume":"12","author":"K Ceonzo","year":"2006","unstructured":"Ceonzo K, Gaynor A, Shaffer L, Kojima K, Vacanti CA, Stahl GL. Polyglycolic acid induced inflammation: role of hydrolysis and resulting complement activation. Tissue Eng. 2006;12:301. https:\/\/doi.org\/10.1089\/TEN.2006.12.301.","journal-title":"Tissue Eng"},{"key":"2117_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/NBT.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941\u201351. https:\/\/doi.org\/10.1038\/NBT.3330.","journal-title":"Nat Biotechnol"},{"key":"2117_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/S10311-014-0466-2","volume":"12","author":"S Rebello","year":"2014","unstructured":"Rebello S, Asok AK, Mundayoor S, Jisha MS. Surfactants: toxicity, remediation and green surfactants. Environ Chem Lett. 2014;12:275\u201387. https:\/\/doi.org\/10.1007\/S10311-014-0466-2.","journal-title":"Environ Chem Lett"},{"key":"2117_CR26","doi-asserted-by":"publisher","DOI":"10.3402\/JEV.V4.30087","volume":"4","author":"T Lener","year":"2015","unstructured":"Lener T, Gimona M, Aigner L, B\u00f6rger V, Buzas E, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087. https:\/\/doi.org\/10.3402\/JEV.V4.30087.","journal-title":"J Extracell Vesicles"},{"key":"2117_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/J.ADDR.2016.02.006","volume":"106","author":"P Vader","year":"2016","unstructured":"Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106:148\u201356. https:\/\/doi.org\/10.1016\/J.ADDR.2016.02.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/JCB.201211138","volume":"200","author":"G Raposo","year":"2013","unstructured":"Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373\u201383. https:\/\/doi.org\/10.1083\/JCB.201211138.","journal-title":"J Cell Biol"},{"key":"2117_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/NRD3978","volume":"12","author":"S El Andaloussi","year":"2013","unstructured":"El Andaloussi S, M\u00e4ger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347\u201357. https:\/\/doi.org\/10.1038\/NRD3978.","journal-title":"Nat Rev Drug Discov"},{"key":"2117_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/S41565-021-00931-2","volume":"16","author":"IK Herrmann","year":"2021","unstructured":"Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748\u201359. https:\/\/doi.org\/10.1038\/S41565-021-00931-2.","journal-title":"Nat Nanotechnol"},{"key":"2117_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15102838","volume":"15","author":"V Johnson","year":"2023","unstructured":"Johnson V, Vasu S, Kumar US, Kumar M. Surface-engineered extracellular vesicles in cancer immunotherapy. Cancers (Basel). 2023;15:2838. https:\/\/doi.org\/10.3390\/CANCERS15102838.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2117_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-025-07077-Y","volume":"23","author":"M Hu","year":"2025","unstructured":"Hu M, Han Y, Zhang X, Tian S, Shang Z, Yuan Z, et al. Extracellular vesicles for targeted drug delivery: advances in surface modification strategies and therapeutic applications. J Transl Med. 2025;23(1):1. https:\/\/doi.org\/10.1186\/S12967-025-07077-Y.","journal-title":"J Transl Med"},{"key":"2117_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/S13287-022-02806-2","volume":"13","author":"A Esmaeili","year":"2022","unstructured":"Esmaeili A, Alini M, Baghaban Eslaminejad M, Hosseini S. Engineering strategies for customizing extracellular vesicle uptake in a therapeutic context. Stem Cell Res Ther. 2022;13:129. https:\/\/doi.org\/10.1186\/S13287-022-02806-2.","journal-title":"Stem Cell Res Ther"},{"key":"2117_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ANBR.202400073","volume":"4","author":"S Uman","year":"2024","unstructured":"Uman S, Weingarten N, Helmers M, Iyengar A, Xu KL, Worthington K, et al. Engineering and monitoring the sustained release of extracellular vesicles from hydrogels for in\u2009vivo therapeutic applications. Adv NanoBiomed Res. 2024;4:2400073. https:\/\/doi.org\/10.1002\/ANBR.202400073.","journal-title":"Adv NanoBiomed Res"},{"issue":"1","key":"2117_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar MA, Baba SK, Sadida HQ, Al Marzooqi S, Jerobin J, Altemani FH, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9(1):27. https:\/\/doi.org\/10.1038\/s41392-024-01735-1.","journal-title":"Signal Transduct Target Ther"},{"key":"2117_CR36","unstructured":"1 new message, (n.d.). https:\/\/www.insightaceanalytic.com\/report\/long-acting-drug-delivery-technologies-services-market\/2565. Accessed 4 Nov 2025."},{"key":"2117_CR37","unstructured":"Long-Acting Drug Delivery Market Forecast Report to 2035, (n.d.). https:\/\/www.globenewswire.com\/news-release\/2025\/08\/27\/3140206\/0\/en\/Long-Acting-Drug-Delivery-Market-Forecast-Report-to-2035-with-Profiles-of-Adare-Pharma-Solutions-AMW-Bostal-Creative-Biolabs-ForDoz-Pharma-Innocore-Integral-BioSystems-Samyang-Biop.html (accessed November 4, 2025)."},{"key":"2117_CR38","unstructured":"Long-Acting Drugs Market Revolutionizing Therapeutics with Sustained-Release Innovations and Emerging Opportunities | Stories | Centre of Excellence for Long-acting Therapeutics | University of Liverpool, (n.d.). https:\/\/www.liverpool.ac.uk\/centre-of-excellence-for-long-acting-therapeutics\/global-news\/stories\/title,1499718,en.php. Accessed 4 Nov 2025."},{"key":"2117_CR39","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1021\/acs.molpharmaceut.4c00665","volume":"21","author":"S Alidori","year":"2024","unstructured":"Alidori S, Subramanian R, Holm R. Patient-centric long-acting injectable and implantable platforms\u2500an industrial perspective. Mol Pharm. 2024;21:4238\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00665.","journal-title":"Mol Pharm"},{"key":"2117_CR40","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/PPA.S87271","volume":"9","author":"JF Jin","year":"2015","unstructured":"Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923. https:\/\/doi.org\/10.2147\/PPA.S87271.","journal-title":"Patient Prefer Adherence"},{"key":"2117_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.SMIM.2007.11.004","volume":"20","author":"JM Anderson","year":"2008","unstructured":"Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20:86\u2013100. https:\/\/doi.org\/10.1016\/J.SMIM.2007.11.004.","journal-title":"Semin Immunol"},{"key":"2117_CR42","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.85563","volume":"17","author":"M Nammas","year":"2025","unstructured":"Nammas M. The impact of drug delivery systems on pharmacokinetics and drug-drug interactions in neuropsychiatric treatment. Cureus. 2025;17:e85563. https:\/\/doi.org\/10.7759\/CUREUS.85563.","journal-title":"Cureus"},{"key":"2117_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","volume":"167","author":"CI Nkanga","year":"2020","unstructured":"Nkanga CI, Fisch A, Rad-Malekshahi M, Romic MD, Kittel B, Ullrich T, et al. Clinically established biodegradable long acting injectables: an industry perspective. Adv Drug Deliv Rev. 2020;167:19\u201346. https:\/\/doi.org\/10.1016\/j.addr.2020.11.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505\u201322. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.043.","journal-title":"J Control Release"},{"key":"2117_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","volume":"28","author":"JM Anderson","year":"1997","unstructured":"Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5\u201324. https:\/\/doi.org\/10.1016\/S0169-409X(97)00048-3.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/S40204-014-0029-4","volume":"3","author":"S D\u2019Souza","year":"2014","unstructured":"D\u2019Souza S, Faraj JA, Giovagnoli S, DeLuca PP. In vitro\u2013in vivo correlation from lactide-co-glycolide polymeric dosage forms. Prog Biomater. 2014;3:131. https:\/\/doi.org\/10.1007\/S40204-014-0029-4.","journal-title":"Prog Biomater"},{"key":"2117_CR47","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1517\/17425247.2016.1134484","volume":"13","author":"JV Andhariya","year":"2016","unstructured":"Andhariya JV, Burgess DJ. Recent advances in testing of microsphere drug delivery systems. Expert Opin Drug Deliv. 2016;13:593\u2013608. https:\/\/doi.org\/10.1517\/17425247.2016.1134484.","journal-title":"Expert Opin Drug Deliv"},{"key":"2117_CR48","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2147\/IJN.S445269","volume":"19","author":"M Wang","year":"2024","unstructured":"Wang M, Wang S, Zhang C, Ma M, Yan B, Hu X, et al. Microstructure formation and characterization of long-acting injectable microspheres: the gateway to fully controlled drug release pattern. Int J Nanomedicine. 2024;19:1571\u201395. https:\/\/doi.org\/10.2147\/IJN.S445269.","journal-title":"Int J Nanomedicine"},{"key":"2117_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS10040263","author":"H Zhong","year":"2018","unstructured":"Zhong H, Chan G, Hu Y, Hu H, Ouyang D. A Comprehensive map of FDA-approved pharmaceutical products. Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/PHARMACEUTICS10040263.","journal-title":"Pharmaceutics"},{"key":"2117_CR50","doi-asserted-by":"publisher","DOI":"10.1208\/S12248-018-0253-2\/FIGURES\/10","volume":"20","author":"J Zhou","year":"2018","unstructured":"Zhou J, Hirota K, Ackermann R, Walker J, Wang Y, Choi S, et al. Reverse engineering the 1-month Lupron Depot\u00ae. AAPS J. 2018;20:105-. https:\/\/doi.org\/10.1208\/S12248-018-0253-2\/FIGURES\/10.","journal-title":"AAPS J"},{"key":"2117_CR51","unstructured":"LUPRON DEPOT (leuprolide acetate for depot suspension), (n.d.). https:\/\/www.lupron.com\/. Accessed 9 Dec 2025."},{"key":"2117_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0022-5347(17)39868-3","volume":"143","author":"R Sharifi","year":"1990","unstructured":"Sharifi R, Soloway M, Correa RJ, Glass AG, Guinan PD, Garnick MB, et al. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J Urol. 1990;143:68\u201371. https:\/\/doi.org\/10.1016\/S0022-5347(17)39868-3.","journal-title":"J Urol"},{"key":"2117_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0015-0282(16)53755-8","volume":"54","author":"AM Dlugi","year":"1990","unstructured":"Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril. 1990;54:419\u201327. https:\/\/doi.org\/10.1016\/S0015-0282(16)53755-8.","journal-title":"Fertil Steril"},{"key":"2117_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/71916","volume":"18","author":"G Zhu","year":"2000","unstructured":"Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide). Nat Biotechnol. 2000;18:52\u20137. https:\/\/doi.org\/10.1038\/71916.","journal-title":"Nat Biotechnol"},{"key":"2117_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.JCONREL.2014.03.053","volume":"190","author":"AC Anselmo","year":"2014","unstructured":"Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15. https:\/\/doi.org\/10.1016\/J.JCONREL.2014.03.053.","journal-title":"J Control Release"},{"key":"2117_CR56","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/APPI.AJP.160.6.1125\/ASSET\/6CEC08B3-89BA-4D6C-937D-04C6DED9E861\/ASSETS\/GRAPHIC\/L716F3.JPEG","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125\u201332. https:\/\/doi.org\/10.1176\/APPI.AJP.160.6.1125\/ASSET\/6CEC08B3-89BA-4D6C-937D-04C6DED9E861\/ASSETS\/GRAPHIC\/L716F3.JPEG.","journal-title":"Am J Psychiatry"},{"key":"2117_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/PR12122858","author":"YJ Son","year":"2024","unstructured":"Son YJ, Yun TH, Lee JG, Bang KH, Kim KS, Son YJ, et al. Development and characterization of long-acting injectable risperidone microspheres using biodegradable polymers: formulation optimization and release kinetics. Processes. 2024. https:\/\/doi.org\/10.3390\/PR12122858.","journal-title":"Processes"},{"key":"2117_CR58","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/JAMA.293.13.1617","volume":"293","author":"JC Garbutt","year":"2005","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617\u201325. https:\/\/doi.org\/10.1001\/JAMA.293.13.1617.","journal-title":"JAMA"},{"key":"2117_CR59","unstructured":"fda, DESCRIPTION, (n.d.). https:\/\/www.fda.gov\/drugsatfda. Accessed 14 Dec 2025."},{"key":"2117_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/NRD1067","volume":"2","author":"M Goldberg","year":"2003","unstructured":"Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2:289\u201395. https:\/\/doi.org\/10.1038\/NRD1067.","journal-title":"Nat Rev Drug Discov"},{"key":"2117_CR61","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2337\/DC09-1914","volume":"33","author":"JB Buse","year":"2010","unstructured":"Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33:1255\u201361. https:\/\/doi.org\/10.2337\/DC09-1914.","journal-title":"Diabetes Care"},{"key":"2117_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2023.115003","volume":"200","author":"AK Pandya","year":"2023","unstructured":"Pandya AK, Vora LK, Umeyor C, Surve D, Patel A, Biswas S, et al. Polymeric in situ forming depots for long-acting drug delivery systems. Adv Drug Deliv Rev. 2023;200:115003. https:\/\/doi.org\/10.1016\/J.ADDR.2023.115003.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR63","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1039\/B713009K","volume":"37","author":"L Yu","year":"2008","unstructured":"Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev. 2008;37:1473\u201381. https:\/\/doi.org\/10.1039\/B713009K.","journal-title":"Chem Soc Rev"},{"key":"2117_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2021.113912","volume":"178","author":"X Wang","year":"2021","unstructured":"Wang X, Burgess DJ. Drug release from in situ forming implants and advances in release testing. Adv Drug Deliv Rev. 2021;178:113912. https:\/\/doi.org\/10.1016\/J.ADDR.2021.113912.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPX.2025.100440","volume":"10","author":"J Siepmann","year":"2025","unstructured":"Siepmann J, Siepmann F. Release mechanisms of PLGA-based drug delivery systems: a review. Int J Pharm X. 2025;10:100440. https:\/\/doi.org\/10.1016\/J.IJPX.2025.100440.","journal-title":"Int J Pharm X"},{"key":"2117_CR66","unstructured":"Dunn RL, Collins F, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in-situ forming implants and methods of producing the same. 1997;51."},{"key":"2117_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/PCAN.2011.50","volume":"15","author":"A Spitz","year":"2011","unstructured":"Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J, Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2011;15:93. https:\/\/doi.org\/10.1038\/PCAN.2011.50.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2117_CR68","first-page":"74","volume":"1","author":"K Malik","year":"2010","unstructured":"Malik K, Singh I, Nagpal M, Arora S. Atrigel: a potential parenteral controlled drug delivery system. Der Pharm Sin. 2010;1:74\u201381.","journal-title":"Der Pharm Sin"},{"key":"2117_CR69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0090-4295(02)02396-8","volume":"61","author":"O Sartor","year":"2003","unstructured":"Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology. 2003;61:25\u201331. https:\/\/doi.org\/10.1016\/S0090-4295(02)02396-8.","journal-title":"Urology"},{"key":"2117_CR70","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"393","author":"BR Haight","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393:778\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)32259-1.","journal-title":"Lancet"},{"key":"2117_CR71","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.JCONREL.2010.08.020","volume":"147","author":"RB Patel","year":"2010","unstructured":"Patel RB, Solorio L, Wu H, Krupka T, Exner AA. Effect of injection site on in situ implant formation and drug release in vivo. J Control Release. 2010;147:350. https:\/\/doi.org\/10.1016\/J.JCONREL.2010.08.020.","journal-title":"J Control Release"},{"key":"2117_CR72","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejpb.2004.03.003","volume":"58","author":"CB Packhaeuser","year":"2004","unstructured":"Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58:445\u201355. https:\/\/doi.org\/10.1016\/j.ejpb.2004.03.003.","journal-title":"Eur J Pharm Biopharm"},{"key":"2117_CR73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/PROS.2990180206","volume":"18","author":"DL Citrin","year":"1991","unstructured":"Citrin DL, Resnick MI, Guinan P, Al\u2010Bussam N, Scott M, Gau TC, et al. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial. Prostate. 1991;18:139\u201346. https:\/\/doi.org\/10.1002\/PROS.2990180206.","journal-title":"Prostate"},{"key":"2117_CR74","unstructured":"fda, cder, Viadur \u00ae (leuprolide acetate implant), (n.d.). https:\/\/www.fda.gov\/drugsatfda. Accessed 14 Dec 2025."},{"key":"2117_CR75","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/S00345-019-02741-7\/TABLES\/5","volume":"38","author":"N Shore","year":"2020","unstructured":"Shore N, Mincik I, DeGuenther M, Student V, Jievaltas M, Patockova J, et al. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. World J Urol. 2020;38:111\u20139. https:\/\/doi.org\/10.1007\/S00345-019-02741-7\/TABLES\/5.","journal-title":"World J Urol"},{"key":"2117_CR76","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14737140.2022.2082947","volume":"22","author":"AS Merseburger","year":"2022","unstructured":"Merseburger AS, Roesch MC. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer. Expert Rev Anticancer Ther. 2022;22:703\u201315. https:\/\/doi.org\/10.1080\/14737140.2022.2082947.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2117_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/S41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2018","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2018;22:24. https:\/\/doi.org\/10.1038\/S41391-018-0079-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2117_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JCONREL.2014.02.006","volume":"181","author":"LW Kleiner","year":"2014","unstructured":"Kleiner LW, Wright JC, Wang Y. Evolution of implantable and insertable drug delivery systems. J Control Release. 2014;181:1\u201310. https:\/\/doi.org\/10.1016\/J.JCONREL.2014.02.006.","journal-title":"J Control Release"},{"key":"2117_CR79","unstructured":"LHRH implant for prostate cancer to be discontinued | Urology Times, (n.d.). https:\/\/www.urologytimes.com\/view\/lhrh-implant-prostate-cancer-be-discontinued. Accessed 14 Dec 2025."},{"key":"2117_CR80","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/J.APSB.2021.05.002","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Lu A, Wang X, Belhadj Z, Wang J, Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B. 2021;11:2396. https:\/\/doi.org\/10.1016\/J.APSB.2021.05.002.","journal-title":"Acta Pharm Sin B"},{"key":"2117_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2023.114901","volume":"199","author":"R Sharma","year":"2023","unstructured":"Sharma R, Yadav S, Yadav V, Akhtar J, Katari O, Kuche K, et al. Recent advances in lipid-based long-acting injectable depot formulations. Adv Drug Deliv Rev. 2023;199:114901. https:\/\/doi.org\/10.1016\/J.ADDR.2023.114901.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPS.2022.106253","volume":"178","author":"J Wilkinson","year":"2022","unstructured":"Wilkinson J, Ajulo D, Tamburrini V, Le Gall G, Kimpe K, Holm R, et al. Lipid based intramuscular long-acting injectables: current state of the art. Eur J Pharm Sci. 2022;178:106253. https:\/\/doi.org\/10.1016\/J.EJPS.2022.106253.","journal-title":"Eur J Pharm Sci"},{"key":"2117_CR83","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2165\/00003495-198733010-00002","volume":"33","author":"R Beresford","year":"1987","unstructured":"Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. 1987;33:31\u201349. https:\/\/doi.org\/10.2165\/00003495-198733010-00002.","journal-title":"Drugs"},{"key":"2117_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/J.NXNANO.2025.100209","volume":"8","author":"R Chelliah","year":"2025","unstructured":"Chelliah R, Rubab M, Vijayalakshmi S, Karuvelan M, Barathikannan K, Oh DH. Liposomes for drug delivery: classification, therapeutic applications, and limitations. Next Nanotechnol. 2025;8:100209. https:\/\/doi.org\/10.1016\/J.NXNANO.2025.100209.","journal-title":"Next Nanotechnol"},{"issue":"2","key":"2117_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.22037\/IJPR.2020.112291.13663","volume":"19","author":"B Salehi","year":"2020","unstructured":"Salehi B, Mishra AP, Nigam M, Kobarfard F, Javed Z, Rajabi S, et al. Multivesicular Liposome (Depofoam) in Human Diseases. Iran J Pharm Res: IJPR. 2020;19(2):9-21.e124653. https:\/\/doi.org\/10.22037\/IJPR.2020.112291.13663.","journal-title":"Iran J Pharm Res: IJPR"},{"key":"2117_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.IJPHARM.2018.12.030","volume":"557","author":"M Breitsamer","year":"2019","unstructured":"Breitsamer M, Winter G. Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: state of the art review. Int J Pharm. 2019;557:1\u20138. https:\/\/doi.org\/10.1016\/J.IJPHARM.2018.12.030.","journal-title":"Int J Pharm"},{"key":"2117_CR87","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/SCS.0000000000004312","volume":"29","author":"KM Day","year":"2018","unstructured":"Day KM, Nair NM, Griner D, Sargent LA. Extended release liposomal bupivacaine injection (EXPAREL) for early postoperative pain control following pharyngoplasty. J Craniofac Surg. 2018;29:726\u201330. https:\/\/doi.org\/10.1097\/SCS.0000000000004312.","journal-title":"J Craniofac Surg"},{"key":"2117_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPB.2024.114577","volume":"205","author":"J Li","year":"2024","unstructured":"Li J, Xia Z, Yu M, Schwendeman A. Challenges in the development of long acting injectable multivesicular liposomes (DepoFoam\u00ae technology). Eur J Pharm Biopharm. 2024;205:114577. https:\/\/doi.org\/10.1016\/J.EJPB.2024.114577.","journal-title":"Eur J Pharm Biopharm"},{"key":"2117_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.ADDR.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351. https:\/\/doi.org\/10.1016\/J.ADDR.2015.09.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS16010028","volume":"16","author":"M Markowicz-Piasecka","year":"2023","unstructured":"Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Ko\u0142odziejczyk M, Grzeli\u0144ska J, Fabija\u0144ska M, et al. Long-acting injectable antipsychotics\u2014a review on formulation and in vitro dissolution. Pharmaceutics. 2023;16:28. https:\/\/doi.org\/10.3390\/PHARMACEUTICS16010028.","journal-title":"Pharmaceutics"},{"key":"2117_CR91","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMOA1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, Pokrovsky V, Overton ET, Girard P-M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124\u201335. https:\/\/doi.org\/10.1056\/NEJMOA1909512.","journal-title":"N Engl J Med"},{"key":"2117_CR92","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMOA1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masi\u00e1 M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112\u201323. https:\/\/doi.org\/10.1056\/NEJMOA1904398.","journal-title":"N Engl J Med"},{"key":"2117_CR93","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396:1994\u20132005. https:\/\/doi.org\/10.1016\/S0140-6736(20)32666-0.","journal-title":"Lancet"},{"key":"2117_CR94","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/JCP.0B013E3181DD3103","volume":"30","author":"GJ Pandina","year":"2010","unstructured":"Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235\u201344. https:\/\/doi.org\/10.1097\/JCP.0B013E3181DD3103.","journal-title":"J Clin Psychopharmacol"},{"key":"2117_CR95","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/JAMAPSYCHIATRY.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72:830\u20139. https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2015.0241.","journal-title":"JAMA Psychiatry"},{"key":"2117_CR96","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/IJNP\/PYAB071","volume":"25","author":"D Najarian","year":"2022","unstructured":"Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25:238\u201351. https:\/\/doi.org\/10.1093\/IJNP\/PYAB071.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2117_CR97","doi-asserted-by":"publisher","first-page":"8587","DOI":"10.2147\/IJN.S513030","volume":"20","author":"MME Aldeeb","year":"2025","unstructured":"Aldeeb MME, Wilar G, Suhandi C, Mohammed AFA, Mahmoud SA, Elamin KM, et al. Emerging trends in the application of nanosuspension-based biomaterials for anticancer drug delivery. Int J Nanomedicine. 2025;20:8587. https:\/\/doi.org\/10.2147\/IJN.S513030.","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"2117_CR98","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41578-021-00405-w","volume":"7","author":"W Li","year":"2022","unstructured":"Li W, Tang J, Lee D, Tice TR, Schwendeman SP, Prausnitz MR. Clinical translation of long-acting drug delivery formulations. Nat Rev Mater. 2022;7(5):406\u201320. https:\/\/doi.org\/10.1038\/s41578-021-00405-w.","journal-title":"Nat Rev Mater"},{"key":"2117_CR99","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/J.DRUDIS.2019.12.008","volume":"25","author":"F Selmin","year":"2020","unstructured":"Selmin F, Musazzi UM, Magri G, Rocco P, Cilurzo F, Minghetti P. Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies. Drug Discov Today. 2020;25:321\u20139. https:\/\/doi.org\/10.1016\/J.DRUDIS.2019.12.008.","journal-title":"Drug Discov Today"},{"key":"2117_CR100","unstructured":"Long-Acting Drugs Market Revolutionizing Therapeutics with Sustained-Release Innovations and Emerging Opportunities | Stories | Centre of Excellence for Long-acting Therapeutics - Global Health | University of Liverpool, (n.d.). https:\/\/www.liverpool.ac.uk\/celt-global-health\/global-news\/stories\/title,1499718,en.php. Accessed 18 Dec 2025."},{"key":"2117_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15102402","author":"DT Abdeldaim","year":"2023","unstructured":"Abdeldaim DT, Schindowski K. Fc-engineered therapeutic antibodies: recent advances and future directions. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15102402.","journal-title":"Pharmaceutics"},{"key":"2117_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS8070727","volume":"8","author":"LM Doyle","year":"2019","unstructured":"Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8:727. https:\/\/doi.org\/10.3390\/CELLS8070727.","journal-title":"Cells"},{"key":"2117_CR103","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/BIOSCI\/BIV084","volume":"65","author":"MP Zaborowski","year":"2015","unstructured":"Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015;65:783\u201397. https:\/\/doi.org\/10.1093\/BIOSCI\/BIV084.","journal-title":"Bioscience"},{"key":"2117_CR104","doi-asserted-by":"publisher","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M, Siljander PRM, Andreu Z, Zavec AB, Borr\u00e0s FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Col\u00e1s E, Cordeiro-Da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NHH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Kr\u00e4mer-Albers EM, Laitinen S, L\u00e4sser C, Lener T, Ligeti E, Line A, Lipps G, Llorente A, L\u00f6tvall J, Man\u010dek-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-\u2019t Hoen ENM, Nyman TA, O\u2019Driscoll L, Olivan M, Oliveira C, P\u00e1llinger \u00c9, Del Portillo HA, Revent\u00f3s J, Rigau M, Rohde E, Sammar M, S\u00e1nchez-Madrid F, Santar\u00e9m N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van Der Grein SG, Helena Vasconcelos M, Wauben MHM, De Wever O. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4. https:\/\/doi.org\/10.3402\/JEV.V4.27066.","DOI":"10.3402\/JEV.V4.27066"},{"key":"2117_CR105","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/J.ADDR.2020.03.002","volume":"159","author":"T Skotland","year":"2020","unstructured":"Skotland T, Sagini K, Sandvig K, Llorente A. An emerging focus on lipids in extracellular vesicles. Adv Drug Deliv Rev. 2020;159:308\u201321. https:\/\/doi.org\/10.1016\/J.ADDR.2020.03.002.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/JEV2.12260","volume":"11","author":"S Hallal","year":"2022","unstructured":"Hallal S, T\u0171zesi \u00c1, Grau GE, Buckland ME, Alexander KL. Understanding the extracellular vesicle surface for clinical molecular biology. J Extracell Vesicles. 2022;11:e12260. https:\/\/doi.org\/10.1002\/JEV2.12260.","journal-title":"J Extracell Vesicles"},{"key":"2117_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/J.NANTOD.2025.102920","volume":"66","author":"HM Baby","year":"2026","unstructured":"Baby HM, Zhang H, Selvadoss A, Pathrikar TV, Bajpayee AG. Rational design of extracellular vesicles for targeted drug delivery across physiological barriers. Nano Today. 2026;66:102920. https:\/\/doi.org\/10.1016\/J.NANTOD.2025.102920.","journal-title":"Nano Today"},{"key":"2117_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/ADHM.202100639","volume":"11","author":"L van der Koog","year":"2022","unstructured":"van der Koog L, Gandek TB, Nagelkerke A. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv Healthc Mater. 2022;11:2100639. https:\/\/doi.org\/10.1002\/ADHM.202100639.","journal-title":"Adv Healthc Mater"},{"issue":"4","key":"2117_CR109","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56(4):836\u201349. https:\/\/doi.org\/10.1038\/s12276-024-01201-6.","journal-title":"Exp Mol Med"},{"issue":"2","key":"2117_CR110","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3390\/IJMS24021337","volume":"24","author":"SV Krylova","year":"2023","unstructured":"Krylova SV, Feng D. The machinery of exosomes: biogenesis, release, and uptake. Int J Mol Sci. 2023;24(2):1337\u20131337. https:\/\/doi.org\/10.3390\/IJMS24021337.","journal-title":"Int J Mol Sci"},{"key":"2117_CR111","doi-asserted-by":"publisher","DOI":"10.5772\/61186","volume":"4","author":"KJ McKelvey","year":"2015","unstructured":"McKelvey KJ, Powell KL, Ashton AW, Morris JM, McCracken SA. Exosomes: mechanisms of uptake. J Circ Biomark. 2015;4:7. https:\/\/doi.org\/10.5772\/61186.","journal-title":"J Circ Biomark"},{"key":"2117_CR112","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1126\/SCIENCE.1153124","volume":"319","author":"K Trajkovic","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244\u20137. https:\/\/doi.org\/10.1126\/SCIENCE.1153124.","journal-title":"Science"},{"key":"2117_CR113","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1074\/JBC.M115.686295","volume":"291","author":"A Purushothaman","year":"2016","unstructured":"Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EA, Sanderson RD. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J Biol Chem. 2016;291:1652\u201363. https:\/\/doi.org\/10.1074\/JBC.M115.686295.","journal-title":"J Biol Chem"},{"key":"2117_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS17081296","author":"I Prada","year":"2016","unstructured":"Prada I, Meldolesi J. Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/IJMS17081296.","journal-title":"Int J Mol Sci"},{"key":"2117_CR115","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/J.BBRC.2014.03.067","volume":"446","author":"M Hazawa","year":"2014","unstructured":"Hazawa M, Tomiyama K, Saotome-Nakamura A, Obara C, Yasuda T, Gotoh T, et al. Radiation increases the cellular uptake of exosomes through CD29\/CD81 complex formation. Biochem Biophys Res Commun. 2014;446:1165\u201371. https:\/\/doi.org\/10.1016\/J.BBRC.2014.03.067.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2117_CR116","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","volume":"21","author":"M Mathieu","year":"2019","unstructured":"Mathieu M, Martin-Jaular L, Lavieu G, Th\u00e9ry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9\u201317. https:\/\/doi.org\/10.1038\/s41556-018-0250-9.","journal-title":"Nat Cell Biol"},{"key":"2117_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS12111022","volume":"12","author":"P Lara","year":"2020","unstructured":"Lara P, Chan AB, Cruz LJ, Quest AFG, Kogan MJ. Exploiting the natural properties of extracellular vesicles in targeted delivery towards specific cells and tissues. Pharmaceutics. 2020;12:1022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS12111022.","journal-title":"Pharmaceutics"},{"key":"2117_CR118","doi-asserted-by":"publisher","DOI":"10.3402\/JEV.V4.26316","author":"OPB Wiklander","year":"2015","unstructured":"Wiklander OPB, Nordin JZ, O\u2019Loughlin A, Gustafsson Y, Corso G, M\u00e4ger I, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015. https:\/\/doi.org\/10.3402\/JEV.V4.26316.","journal-title":"J Extracell Vesicles"},{"key":"2117_CR119","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/CIRCRESAHA.123.323054\/ASSET\/25F7DF1E-9076-44DE-B3FA-EB2DE0C2EDA3\/ASSETS\/GRAPHIC\/CIRCRESAHA.123.323054.FIG06.JPG","volume":"135","author":"A Rai","year":"2024","unstructured":"Rai A, Claridge B, Lozano J, Greening DW. The discovery of extracellular vesicles and their emergence as a next-generation therapy. Circ Res. 2024;135:198\u2013221. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.323054\/ASSET\/25F7DF1E-9076-44DE-B3FA-EB2DE0C2EDA3\/ASSETS\/GRAPHIC\/CIRCRESAHA.123.323054.FIG06.JPG.","journal-title":"Circ Res"},{"key":"2117_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/FBIOE.2025.1600227\/XML","volume":"13","author":"T Chen","year":"2025","unstructured":"Chen T, Chen D, Su W, Liang J, Liu X, Cai M. Extracellular vesicles as vital players in drug delivery: a focus on clinical disease treatment. Front Bioeng Biotechnol. 2025;13:1600227. https:\/\/doi.org\/10.3389\/FBIOE.2025.1600227\/XML.","journal-title":"Front Bioeng Biotechnol"},{"key":"2117_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/J.MTNANO.2021.100148","volume":"16","author":"BS Joshi","year":"2021","unstructured":"Joshi BS, Ortiz D, Zuhorn IS. Converting extracellular vesicles into nanomedicine: loading and unloading of cargo. Mater Today Nano. 2021;16:100148. https:\/\/doi.org\/10.1016\/J.MTNANO.2021.100148.","journal-title":"Mater Today Nano"},{"key":"2117_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS10040218","volume":"10","author":"SG Antimisiaris","year":"2018","unstructured":"Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10:218. https:\/\/doi.org\/10.3390\/PHARMACEUTICS10040218.","journal-title":"Pharmaceutics"},{"key":"2117_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/S12951-023-02064-1","author":"X Liu","year":"2023","unstructured":"Liu X, Xiao C, Xiao K. Engineered extracellular vesicles-like biomimetic nanoparticles as an emerging platform for targeted cancer therapy. J Nanobiotechnology. 2023. https:\/\/doi.org\/10.1186\/S12951-023-02064-1.","journal-title":"J Nanobiotechnology"},{"key":"2117_CR124","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/J.ADDR.2021.03.020","volume":"173","author":"M Richter","year":"2021","unstructured":"Richter M, Vader P, Fuhrmann G. Approaches to surface engineering of extracellular vesicles. Adv Drug Deliv Rev. 2021;173:416\u201326. https:\/\/doi.org\/10.1016\/J.ADDR.2021.03.020.","journal-title":"Adv Drug Deliv Rev"},{"key":"2117_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/S13046-025-03403-W","volume":"44","author":"Z Gong","year":"2025","unstructured":"Gong Z, Cheng C, Sun C, Cheng X. Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy. J Exp Clin Cancer Res. 2025;44:138. https:\/\/doi.org\/10.1186\/S13046-025-03403-W.","journal-title":"J Exp Clin Cancer Res"},{"key":"2117_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES9080823","author":"A Do Minh","year":"2021","unstructured":"Do Minh A, Kamen AA. Critical assessment of purification and analytical technologies for enveloped viral vector and vaccine processing and their current limitations in resolving co-expressed extracellular vesicles. Vaccines. 2021. https:\/\/doi.org\/10.3390\/VACCINES9080823.","journal-title":"Vaccines"},{"key":"2117_CR127","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11:3183\u201395. https:\/\/doi.org\/10.7150\/thno.52570.","journal-title":"Theranostics"},{"issue":"12","key":"2117_CR128","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/nprot.2012.131","volume":"7","author":"S El-Andaloussi","year":"2012","unstructured":"El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C, et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc. 2012;7(12):2112\u201326. https:\/\/doi.org\/10.1038\/nprot.2012.131.","journal-title":"Nat Protoc"},{"key":"2117_CR129","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/J.OMTN.2017.04.010","volume":"7","author":"J Yang","year":"2017","unstructured":"Yang J, Zhang X, Chen X, Wang L, Yang G. Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Mol Ther Nucleic Acids. 2017;7:278\u201387. https:\/\/doi.org\/10.1016\/J.OMTN.2017.04.010.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2117_CR130","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/J.BIOMATERIALS.2013.11.083","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35:2383\u201390. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2013.11.083.","journal-title":"Biomaterials"},{"key":"2117_CR131","doi-asserted-by":"publisher","first-page":"32421","DOI":"10.1021\/ACSNANO.4C04730","volume":"18","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yang K, Huang Z, Wang Y, Xiao A, Jiang X, et al. Efficient, high-quality engineering of therapeutic extracellular vesicles on an integrated nanoplatform. ACS Nano. 2024;18:32421\u201337. https:\/\/doi.org\/10.1021\/ACSNANO.4C04730.","journal-title":"ACS Nano"},{"key":"2117_CR132","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.TIPS.2024.02.006","volume":"45","author":"Z Erana-Perez","year":"2024","unstructured":"Erana-Perez Z, Igartua M, Santos-Vizcaino E, Hernandez RM. Genetically engineered loaded extracellular vesicles for drug delivery. Trends Pharmacol Sci. 2024;45:350\u201365. https:\/\/doi.org\/10.1016\/J.TIPS.2024.02.006.","journal-title":"Trends Pharmacol Sci"},{"key":"2117_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/JEV2.12490","author":"R Chen","year":"2024","unstructured":"Chen R, Kang Z, Li W, Xu T, Wang Y, Jiang Q, et al. Extracellular vesicle surface display of \u03b1PD-L1 and \u03b1CD3 antibodies via engineered late domain-based scaffold to activate T-cell anti-tumor immunity. Journal of Extracellular Vesicles. 2024. https:\/\/doi.org\/10.1002\/JEV2.12490.","journal-title":"Journal of Extracellular Vesicles"},{"key":"2117_CR134","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.3390\/IJMS24087287","volume":"24","author":"A Oshchepkova","year":"2023","unstructured":"Oshchepkova A, Zenkova M, Vlassov V. Extracellular vesicles for therapeutic nucleic acid delivery: loading strategies and challenges. Int J Mol Sci. 2023;24:7287. https:\/\/doi.org\/10.3390\/IJMS24087287.","journal-title":"Int J Mol Sci"},{"key":"2117_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2021.05.011","volume":"175","author":"P Escud\u00e9 Martinez de Castilla","year":"2021","unstructured":"Escud\u00e9 Martinez de Castilla P, Tong L, Huang C, Sofias AM, Pastorin G, Chen X, et al. Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. Advanced Drug Delivery Reviews. 2021;175:113801. https:\/\/doi.org\/10.1016\/J.ADDR.2021.05.011.","journal-title":"Advanced Drug Delivery Reviews"},{"key":"2117_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS17050641","volume":"17","author":"S Mohak","year":"2025","unstructured":"Mohak S, Fabian Z. Extracellular vesicles as precision delivery systems for biopharmaceuticals: innovations, challenges, and therapeutic potential. Pharmaceutics. 2025;17:641. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17050641.","journal-title":"Pharmaceutics"},{"key":"2117_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.BIOACTMAT.2024.04.007","volume":"38","author":"MH Fan","year":"2024","unstructured":"Fan MH, Pi JK, Zou CY, Jiang YL, Li QJ, Zhang XZ, et al. Hydrogel-exosome system in tissue engineering: a promising therapeutic strategy. Bioact Mater. 2024;38:1\u201330. https:\/\/doi.org\/10.1016\/J.BIOACTMAT.2024.04.007.","journal-title":"Bioact Mater"},{"key":"2117_CR138","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/J.JCONREL.2023.01.060","volume":"355","author":"SM van de Looij","year":"2023","unstructured":"van de Looij SM, de Jong OG, Vermonden T, Lorenowicz MJ. Injectable hydrogels for sustained delivery of extracellular vesicles in cartilage regeneration. J Control Release. 2023;355:685\u2013708. https:\/\/doi.org\/10.1016\/J.JCONREL.2023.01.060.","journal-title":"J Control Release"},{"key":"2117_CR139","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.1021\/acsomega.3c08280","volume":"9","author":"A Hashemi","year":"2024","unstructured":"Hashemi A, Ezati M, Nasr MP, Zumberg I, Provaznik V. Extracellular vesicles and hydrogels: an innovative approach to tissue regeneration. ACS Omega. 2024;9:6184\u2013218. https:\/\/doi.org\/10.1021\/acsomega.3c08280.","journal-title":"ACS Omega"},{"key":"2117_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121169","volume":"278","author":"FX Zhang","year":"2021","unstructured":"Zhang FX, Liu P, Ding W, Meng QB, Su DH, Zhang QC, et al. Injectable mussel\u2010inspired highly adhesive hydrogel with exosomes for endogenous cell recruitment and cartilage defect regeneration. Biomaterials. 2021;278:121169. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121169.","journal-title":"Biomaterials"},{"key":"2117_CR141","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1016\/j.bioactmat.2021.04.031","volume":"6","author":"SC Tao","year":"2021","unstructured":"Tao SC, Huang JY, Gao Y, Li ZX, Wei ZY, Dawes H, et al. Small extracellular vesicles in combination with sleep-related circRNA3503: a targeted therapeutic agent with injectable thermosensitive hydrogel to prevent osteoarthritis. Bioact Mater. 2021;6:4455\u201369. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.04.031.","journal-title":"Bioact Mater"},{"key":"2117_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020832","volume":"23","author":"K Man","year":"2022","unstructured":"Man K, Barroso IA, Brunet MY, Peacock B, Federici AS, Hoey DA, et al. Controlled release of epigenetically-enhanced extracellular vesicles from a GelMA\/nanoclay composite hydrogel to promote bone repair. Int J Mol Sci. 2022;23:832. https:\/\/doi.org\/10.3390\/ijms23020832.","journal-title":"Int J Mol Sci"},{"key":"2117_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105586","volume":"9","author":"L Fan","year":"2022","unstructured":"Fan L, Liu C, Chen X, Zheng L, Zou Y, Wen H, et al. Exosomes-loaded electroconductive hydrogel synergistically promotes tissue repair after spinal cord injury via immunoregulation and enhancement of myelinated axon growth. Adv Sci. 2022;9:2105586. https:\/\/doi.org\/10.1002\/advs.202105586.","journal-title":"Adv Sci"},{"key":"2117_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.146238","volume":"475","author":"H Peng","year":"2023","unstructured":"Peng H, Li H, Zhang X, Tang J, Liang Y, Qiao L, et al. 3D-exosomes laden multifunctional hydrogel enhances diabetic wound healing via accelerated angiogenesis. Chem Eng J. 2023;475:146238. https:\/\/doi.org\/10.1016\/j.cej.2023.146238.","journal-title":"Chem Eng J"},{"key":"2117_CR145","doi-asserted-by":"publisher","unstructured":"Man K, Barroso IA, Brunet MY, Peacock B, Federici AS, Hoey DA, Cox SC. Controlled release of epigenetically-enhanced extracellular vesicles from a GelMA\/Nanoclay composite hydrogel to promote bone repair. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/IJMS23020832.","DOI":"10.3390\/IJMS23020832"},{"key":"2117_CR146","doi-asserted-by":"publisher","unstructured":"Bhatta R, Han J, Liu Y, Bo Y, Wang Y, Nguyen D, Chen Q, Wang H. Injectable extracellular vesicle hydrogels with tunable viscoelasticity for depot vaccine. Nat Commun. 2025;16(1):3781-. https:\/\/doi.org\/10.1038\/s41467-025-59278-0.","DOI":"10.1038\/s41467-025-59278-0"},{"key":"2117_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/gels8060328","volume":"8","author":"Y Xie","year":"2022","unstructured":"Xie Y, Guan Q, Guo J, Chen Y, Yin Y, Han X. Hydrogels for exosome delivery in biomedical applications. Gels. 2022;8:328. https:\/\/doi.org\/10.3390\/gels8060328.","journal-title":"Gels"},{"key":"2117_CR148","doi-asserted-by":"publisher","first-page":"6830","DOI":"10.1039\/C6TB01560C","volume":"4","author":"M Li","year":"2016","unstructured":"Li M, Ke QF, Tao SC, Guo SC, Rui BY, Guo YP. Fabrication of hydroxyapatite\/chitosan composite hydrogels loaded with exosomes derived from miR-126-3p overexpressed synovial mesenchymal stem cells for diabetic chronic wound healing. J Mater Chem B. 2016;4:6830\u201341. https:\/\/doi.org\/10.1039\/C6TB01560C.","journal-title":"J Mater Chem B"},{"key":"2117_CR149","doi-asserted-by":"publisher","unstructured":"Tang J, Cui X, Zhang Z, Xu Y, Guo J, Soliman BG, Lu Y, Qin Z, Wang Q, Zhang H, Lim KS, Woodfield TBF, Zhang J. Injection-free delivery of MSC-derived extracellular vesicles for myocardial infarction therapeutics. Adv Healthc Mater. 2022:11. https:\/\/doi.org\/10.1002\/ADHM.202100312.","DOI":"10.1002\/ADHM.202100312"},{"key":"2117_CR150","doi-asserted-by":"publisher","first-page":"8694","DOI":"10.1021\/ACSNANO.9B00376\/SUPPL_FILE\/NN9B00376_SI_001.PDF","volume":"13","author":"H Henriques-Antunes","year":"2019","unstructured":"Henriques-Antunes H, Cardoso RMS, Zonari A, Correia J, Leal EC, Jim\u00e9nez-Balsa A, et al. The kinetics of small extracellular vesicle delivery impacts skin tissue regeneration. ACS Nano. 2019;13:8694\u2013707. https:\/\/doi.org\/10.1021\/ACSNANO.9B00376\/SUPPL_FILE\/NN9B00376_SI_001.PDF.","journal-title":"ACS Nano"},{"key":"2117_CR151","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/J.ACTBIO.2021.03.030","volume":"126","author":"CC Huang","year":"2021","unstructured":"Huang CC, Kang M, Shirazi S, Lu Y, Cooper LF, Gajendrareddy P, et al. 3D encapsulation and tethering of functionally engineered extracellular vesicles to hydrogels. Acta Biomater. 2021;126:199\u2013210. https:\/\/doi.org\/10.1016\/J.ACTBIO.2021.03.030.","journal-title":"Acta Biomater"},{"key":"2117_CR152","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/J.TIBTECH.2023.01.003","volume":"41","author":"PM Pincela Lins","year":"2023","unstructured":"Pincela Lins PM, Pirlet E, Szymonik M, Bronckaers A, Nelissen I. Manufacture of extracellular vesicles derived from mesenchymal stromal cells. Trends Biotechnol. 2023;41:965\u201381. https:\/\/doi.org\/10.1016\/J.TIBTECH.2023.01.003.","journal-title":"Trends Biotechnol"},{"key":"2117_CR153","doi-asserted-by":"publisher","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbr\u00fcgger U, Falcon-Perez JM, Fu QL, Hill AF, Lenassi M, Lim SK, Mahoney M\u1ef9G, Mohanty S, M\u00f6ller A, Nieuwland R, Ochiya T, Sahoo S, Torrecilhas AC, Zheng L, Zijlstra A, Abuelreich S, Bagabas R, Bergese P, Bridges EM, Brucale M, Burger D, Carney RP, Cocucci E, Crescitelli R, Hanser , Harris AL, Haughey NJ, Hendrix A, Ivanov AR, Jovanovic-Talisman T, Kruh-Garcia NA, Faustino VKL, Kyburz D, L\u00e4sser C, Lennon KM, L\u00f6tvall J, Maddox AL, Martens-Uzunova ES, Mizenko RR, Newman LA, Ridolfi A, Rohde E, Rojalin T, Rowland A, Saftics A, Sandau US, Saugstad JA, Shekari F, Swift S, Ter-Ovanesyan D, Tosar JP, Useckaite Z, Valle F, Varga Z, van der Pol E, van Herwijnen MJC, Wauben MHM, Wehman AM, Williams S, Zendrini A, Zimmerman AJ, Th\u00e9ry C, Witwer KW, Ahmad S, Ahmed DAK, Ahmed SH, Aikawa E, Akbar N, Akiyoshi K, Al-Adra DP, Al-Masawa ME, Albanese M, Alberro A, Alcaraz MJ, Alexander-Brett J, Alexander KL, Ali N, Alibhai FJ, Allelein S, Allenby MC, Almeida F, de Almeida LP, Almousa SW, Altan-Bonnet N, Altei WF, Alvarez-Llamas G, Alvarez CL, An HJ, Anand K, Andaloussi SEL, Anderson JD, Andriantsitohaina R, Ansari KI, Anselmo A, Antoniou A, Aqil F, Arab T, Archer F, Arif S, Armstrong DA, Arntz OJ, Ars\u00e8ne P, Arteaga-Blanco L, Asokan N, Aspelin T, Atkin-Smith GK, Aubert D, Ayyar KK, Azlan M, Azoidis I, B\u00e9cot A, Bach JM, Bachurski D, Bae S, Bagge RO, Baj-Krzyworzeka M, Balaj L, Balbi C, van Balkom BWM, Ballal AR, Bano A, Banzet S, Bare Y, Barile L, Barman B, Barranco I, Barreca V, Bart G, Barteneva NS, Basso M, Batish M, Bauer NR, Baxter AA, Bazi\u00e9 WW, Bazzan E, Beaumont JEJ, Bebawy M, Bebelman MP, Bedina-Zavec A, Beetler DJ, Beke-Somfai T, Belleann\u00e9e C, Benedikter BJ, Benediktsd\u00f3ttir BE, Berardi AC, Bergamelli M, Bertolini I, Bhattacharyya A, Bhattacharyya SN, Biller SJ, Billottet C, Bissler JJ, Blanc-Brude O, Blijdorp CJ, Bobis-Wozowicz S, Bodart-Santos V, Bodn\u00e1r BR, Boilard E, Boireau W, Bokun V, Bollard SM, Bollini S, Bongiovanni A, Bongiovanni L, Bonifay A, Boppart MD, Borr\u00e0s FE, Bosch S, Boselli D, Bottini M, Bouffard J, Boulanger CM, Boutros PC, Boyadjian O, Boysen AT, Bozkurt BT, Bramich KP, Braun F, Del Carmen Bravo-Miana R, Breakefield XO, Brenna S, Brennan K, Brennan M, Breyne K, Brigstock DR, Brisson AR, Brodie C, Bruno KA, Bucci C, Buch S, Buck A, Bukva M, Bulte JWM, Buratta S, Burgy O, Burnier JV, Burrows K, Busatto S, Buzas K, Byrd JB, C\u00e1ceres-Verschae A, Caires HR, Campos-Silva C, Camussi G, de Candia P, Carceller C, Fernandez-Becerra C, Carrasco AGM, Carter DRF, Cavallaro S, Cavallero S, Cavallero S, Cerda-Troncoso C, Chahwan R, Chalupsk\u00e1 R, Chamley LW, Chandra PK, Chang WW, Charest A, Chen C, Chen H, Chen Q, Chen S, Chen S, Chen Y, Cheng L, Chernyshev VS, Chetty VK, Chitti SV, Cho SG, Cho YK, Choi BH, Chutipongtanate S, Cicardi ME, Cifuentes-Rius A, Ciullo A, Clayton A, Cleary JA, Cocozza F, Coffey RJ, Collino F, Colombo F, Colosetti P, Compa\u00f1-Bertomeu A, Constanzo J, Corbeil D, Cordeiro-da-Silva A, Costa J, Couch Y, Courageux Y, Coutant K, Coyle B, Cretich M, Cronemberger-Andrade A, Crossland RE, Cucher MA, Czystowska-Kuzmicz M, D\u2019Acunzo P, D\u2019Agnano I, D\u2019Agostino VG, D\u2019Arrigo D, D\u2019Souza-Schorey C, Dagur RS, Danielson KM, Das S, Dauphin T, Davidson SM, Davies OG, Davies RL, Davis CN, Deep G, Degosserie J, Van Delen M, Deliwala V, Dellar ER, Van Deun J, Dev A, Deville S, Devitt A, Dhondt B, Dieterich LC, Dittmer DP, Dobosh B, Dobra G, Dogra N, Dohi E, Dolo V, Domashevich TV, Dominici M, Dong L, Dor\u00e9 E, Dragovic RA, Drittanti L, Droste M, Duan W, Durmaz E, Dutta S, Eguchi T, Eichenberger RM, Eitan E, Ekstr\u00f6m K, Eldh M, Elie-Caille C, Enciso-Martinez A, Esmaeili R, Ettelaie C, F\u00f6rs\u00f6nits AI, Fabbri M, Falasca M, Fan H, Fatima F, Fazeli A, Fern\u00e1ndez-Rhodes M, Fernandez-Prada C, Ferraro MJ, Ferreira J, Ferreira RF, Figueroa-Hall LK, Figueroa-Vald\u00e9s AI, Fioretti PV, Flenady S, Flores-Bellver M, Fok EK, Fonseka P, Forbes K, Ford VJ, Fornaguera C, Forte D, Forte S, Fortunato O, Franklin JL, Freitas D, Frelet-Barrand A, Fujita Y, G\u00e4rtner K, G\u00f6rgens A, Gabriel \u00c1M, Gabrielli M, Gabrielsson S, Galinsoga A, Galisova A, Gamage T.KJB, Gao Y, Garcia-Contreras M, Garcia Garcia MM, Garcia MN, Gargiulo E, Garibotti HGK, Mc Gee MM, Genard GC, Geraci F, Ghanam J, Ghatak S, Ghavami M, Ghebosu RE, Gho YS, Ghosal S, Giamas G, Giebel B, Gilbert C, Gimona M, Gir\u00e3o H, Giusti I, Gizzie EA, Glamo\u010dlija S, Glass SE, Gobbo J, Godbole N, Goetz JG, Gololobova O, Gomez-Florit M, Goncalves JP, Gorgun C, Gori A, Gorska S, Graner MW, Grau GE, Grech L, Greening DW, Gro\u00df RM, Gross JC, Gruber J, Gualerzi A, Guanzon D, Gudbergsson JM, Guerin CL, Guerra F, Guill\u00e9n MI, Gujar V, Guo W, Gupta VB, Gupta VK, Gustafson D, Gyukity-Sebesty\u00e9n E, H\u00f6lker P, Hade MD, Hagey DW, Han C, Han P, Hanayama R, Handberg A, Harada M, Harmati M, Harrison P, Harrison RA, Haynes PA, He M, Hegyesi H, van Herwijnen MJC, Hisey CL, Hochberg FH, Nolte-\u2019tHoen ENMN, Holcar M, Holder B, Holnthoner W, Holthofer , Hooper DC, Hosseini-Beheshti E, Hosseinkhani B, Howard J, Howe KL, Hoyle NR, Hrdy J, Hu G, Huang Y, Huber V, Hudoklin S, Hufnagel A, Hulett MD, Hunt S, Hyenne V, Di Ianni E, Iannotta D, Ibrahim AGE, Ibrahim SA, Ikezu S, Ikezu T, Im H, Inal JM, Inic-Kanada A, Inngjerdingen M, Inoshima Y, Ivanova A, Izquierdo E, J\u00f8rgensen MM, Jackson HK, Jacobsen S, Jadue F, Javeed N, Jay SM, Jayachandran M, Jayasinghe MK, Jenster G, Jeppesen DK, Jer\u00f3nimo C, Jiang L, Jin J, Jingushi K, Jo DG, Joerger-Messerli MS, Jones JC, Jones MK, de Jong OG, Ferrante AW, Coleman LG, Juncker D, Jung S, Jurek B, Jurga M, Justilien V, Kabani M, Kalluri R, Kamali-Moghaddam M, Kanada M, Kang T, Kano SI, Kaparakis-Liaskos M, Karnas E, Karoichan A, Kashanchi F, Kashani SA, Kashyap NN, Katsur M, Kau-Strebinger S, Kauffman AC, Kaur S, Kehoe O, Kelwick RJR, Kenari AN, Kestecher BM, Keulers TG, Van Keuren-Jensen KR, Khalaj K, Khamari D, Khanabdali R, Khomyakova E, Khoo A, Kim DH, Kim D, Kim HS, Kim IS, Kim S, Kim Y, Kima PE, Kislinger T, Klingeborn M, Knight R, Komuro H, Koncz A, Konstantinou T, van der Koog L, Kooijmans SAA, Kornek MT, Kosanovi\u0107 M, Kostallari E, Koukoulis TF, Kourembanas S, Kr\u00e4meralbers EM, Kralj-Iglic V, Krasemann S, Krasnodembskaya AD, Krawczynska NJ, Kreft ME, Kuehn MJ, Kuipers ME, Kulaj K, Kuligowski J, Kumagai Y, Kumar A, Kumar S, Kumar S, Kumari M, Kundrotas G, Kurochkin IV, Kuroda M, Kurzawa-Akanbi M, Kweskin SJ, L\u00e1zaro-Ib\u00e1\u00f1ez E, L\u0151rincz \u00c1, Lai A, Lai CP, Laitinen S, Landreville S, Lange S, Langevin SM, Langlois MA, Languino LR, Lannigan J, Lark DS, Larregina AT, Laurent LC, Laurin D, Lavieu G, Lawson C, Le Lay S, Leandro K, Ledreux A, Lee C, Lee DS, Lee H, Lee H, Lee SY, Lee TR, Lee WL, Lefterov I, Lei X, Leivo J, Lemaire Q, Leme AFP, Lemon SM, Lenzini S, Leor J, Levy E, Li B, Li G, Li JJ, Li Q, Li X, Liang X, Lim R, Limongi T, Lin\u0113 A, Lins PP, Lippens L, Liu G, Llorente A, Longjohn MN, van de Loo FAJ, Lorenowicz MJ, Lorico A, Loudig O, Loyer X, Lozano-Andr\u00e9s E, Lu B, Lu Q, Lubart Q, Lucien F, Lunavat TR, Lundberg LE, Lundy DJ, Luoto JC, Lyden DC, M\u00fcller JA, Macphee DJ, Madec E, Maga\u00f1a SM, Mahairaki V, Mahoney M\u1ef9G, Malhi H, Malnou CE, Mamand DR, Man K, Manno M, Mantel PY, Marangon T, Marb\u00e1n E, Marcilla A, Maremanda KP, Margolis L, Mari\u00f1as-Pardo L, Mari\u0107 I, Mart\u00edn SS, Mart\u00ednez-Mart\u00ednez E, Martel C, Martin-Duque P, Martin-Jaular L, Martinez-Murillo PA, Martinez-Pacheco S, Martins-Marques T, Mary B, Marzan AL, Matamoros-Angles A, Mathivanan S, Matsuzaki J, Mayan MD, Mazzeo C, Mbengue M, McCann MJ, McIlvenna LC, McVey MJ, Meisner-Kober N, Mellergaard M, Melli G, Menck K, Menjivar NG, Menon R, Mentkowski KI, Miklavcic JJ, Miklosi AG, Milutinovic B, Minciacchi VR, Mirzaei M, Mishra S, Mitchell MI, Mladenovi\u0107 D, Mohamadi E, Momen-Heravi F, Mondal SK, Mongui\u00f3-Tortajada M, Moon J, Morandi MI, Moreau V, Moreira LR, Morelli AE, Mori MA, Morimoto M, Mosser M, Motaung TE, Moussay E, Mugoni V, Mullier F, Muraca M, Murugesan S, Musante L, Music\u00f2 A, N\u00e9meth A, N\u00e9meth K, Nadeau A, Nam GH, Naora H, Natoli R, Nawaz M, Nazarenko I, Ndukaife JC, Nedeva C, Nejsum P, Nelissen I, Neri C, Neri T, Neviani P, Ng CY, van Niel G, Nikiforova N, Nimrichter L, Nitin C, Njock MS, No\u00ebl D, Noghero A, Nolan JP, Noppen S, Noren Hooten N, da Silva Novaes A, O\u2019loghlen A, Oesterreicher J, Oh SW, Ol\u00e1h A, Olivier M, Ong SL, Ortiz A, Ortiz LA, \u00d8stergaard O, Osorio OA, Osteikoetxea X, Ostrowski M, Otaegui D, Otahal A, Ozawa PMM, Ozkocak DC, P\u00e1l\u00f3czi K, P\u00e9rez-Gonz\u00e1lez R, Pachane BC, Padinharayil H, Paget D, Paggetti J, Palacio PCL, Pallasch CP, Palmulli R, Pang B, Paniushkina L, Pantazi P, Paolini L, Papademetrio DL, Parisse P, Park DJ, Park J, Park YG, Patton JG, Peake J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Pfeiffer A, Phan TK, Phinney DG, Phylactou LA, Picciolini S, Pietrowska M, Piffoux M, Pinheiro C, Pink RC, Pleet ML, Pocsfalvi G, Poh QH, Poojary G, Poon IKH, Poppa G, Del Portillo HA, Pospichalova V, Potter S, Powell BH, Powis SJ, Prada I, Prasadam I, Preu\u00dfer C, Pua HH, Pucci F, Puhm F, Puig B, Pulliam L, Purnianto A, Puutio JMM, Quilang RC, Rabbani PS, Rackov G, Radeghieri A, Radu CM, Raffai RL, Raghav A, Rahbari M, Rahman MDM, Rahman MM, Rai AJ, Raimondo S, Raju S, Rak J, Ramaswamy L, Ramirezricardo J, Ramirez MI, Rani S, Raposo G, Rather HA, Razim A, Reale A, Reategui E, Reddel CJ, Reddy SK, Redenti S, Reed SL, Regevrudzki N, Reiners KS, Resnik N, Rice GE, Ricklefs FL, Rilla K, Rimmer MP, Roballo KCS, Robbins PD, Roberts DD, Roca J, Rodal AA, Rodrigues-Junior DM, Rodrigues ML, Roefs MT, Rogers RG, Romani R, Romano M, Rome S, Romih R, Romolo A, De Rossi T, Rouschop KM, Routenberg DA, Roux Q, van Royen ME, Rozo AJ, Rufino-Ramos D, Rughetti A, Russell AE, Rutter SF, Rysmakhanov MS, S\u00e1nchez CA, Sadovsky Y, Safavi-Sohi R, Sagar R, Saidu NEB, Saint-Pol J, Salas-Huenuleo E, Salazar-Puerta AI, Saleem A, Salekdeh GH, Salomon C, Salviano-Silva A, Salybekov AA, Samuels M, Santavanond JP, Santoro J, Santos M, Sanwlani R, Saul MJ, Sch\u00f8yen TH, Schabussova I, Scharrig E, Schekman R, Schiavi-Tritz J, Schiffelers RM, Schmid AM, Schneider R, Schneider S, Schoeberlein A, Schorey JS, Seo N, Seras-Franzoso J, Shahi S, Shatnyeva O, Shea DF, Shelke GV, Shetty AK, Shiba K, Shiju TM, Shrivastava S, Shukla S, Siljander PRM, Silva AM, Singh AP, Singh S, Skliar M, Skog J, Sluijter JPG, Snyder OL, Soekmadji C, Somaida A, Somiya M, Soroczy\u0144ska K, Sotillo J, Souza-Fonseca-guimaraes F, Spada S, Spiers HVM, Spitzberg JD, Srivastava A, Srivastava AK, St\u0119pie\u0144 E, St-Denis-bissonnette F, Stahl PD, Stam J, Stambouli O, Stanton BA, Stassen FRM, Staufer O, Steiner L, Stepanova G, Stoka V, Stoorvogel W, von Strandmann EP, Strunk D, Stylli SS, Su H, Subramanian S, Sui B, Sukreet S, Sulaiman E, Sung BH, Sunkara V, Suo Z, Svenningsen P, Swatler J, Symonds EKC, Szeifert V, Szigy\u00e1rt\u00f3 IC, T\u00f3th E, Ta\u0282li NP, Tahara H, Takahashi RU, Takakura Y, Takikawa O, Takov K, Tang VA, Taverna S, Tawil N, Teeuwen L, Tejedor S, Tertel T, Thakur A, Thompson-Felix T, Tian C, Tikhonov A, Tiwari S, Toh WS, Tomes JJ, Tonoli E, Trinidad CV, Tritten L, Trivedi R, Troyer Z, Tsamchoe M, Tscherrig V, Tsering T, Turkova K, Tutanov OS, Ueda K, Upadhya D, Urabe F, Urbanelli L, Urz\u00ec O, Vacchi E, Vader P, Vago R, Valadi H, Valkonen S, Varas-Godoy M, Varga Z, Vasconcelos MH, Vechetti IJ, Veiga SI, Vella LJ, Velot \u00c9, Verweij FJ, Vestad B, Vinay L, Viola M, Visnovitz T, Vreeland WN, Vukman KV, Wade PK, van de Wakker SI, Walther L, Wang T, Wang X, Watson DC, Weaver AM, Webber JP, Weber V, Weiss L, Weiss ML, Weiss R, Weissleder R, Wen Y, de Wever O, Wheelock AM, White KE, Whitehead B, Whiteside TL, Whitley J, Wiener Z, Van Wijnen AJ, Wiklander OPB, Winston CN, Wolf M, Wolfram J, Wu L, Wu Y, Wysmo\u0142ek ME, Xander P, Xavier CPR, Xiao Y, Xu R, Y\u00e1\u00f1ez-M\u00f3 M, Yamamoto T, Yamamoto Y, Yamamoto Y, Yan X, Yang L, Yang Y, Yarani R, Yea K, Yedigaryan L, Yenuganti VR, Yerneni SS, Yeung V, Yildizhan Y, Yin H, Yokoi A, Yoshioka Y, You Y, Yuan LQ, Yunga ST, Zakeri A, Zani A, Zanoni M, Zappulli V, Zarovni N, Zarubova J, Zempleni J, \u017d\u0117kas V, Zhang H, Zhang Q, Zhao Z, Zhou Y, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK, Zubair H. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404. https:\/\/doi.org\/10.1002\/JEV2.12404.","DOI":"10.1002\/JEV2.12404"},{"issue":"1","key":"2117_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02312-w","volume":"10","author":"G Xu","year":"2025","unstructured":"Xu G, Jin J, Fu Z, Wang G, Lei X, Xu J, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct Target Ther. 2025;10(1):10. https:\/\/doi.org\/10.1038\/s41392-025-02312-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2117_CR155","doi-asserted-by":"publisher","first-page":"80","DOI":"10.20517\/EVCNA.2021.07","volume":"2","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Wijerathne H, Godwin AK, Soper SA. Isolation and analysis methods of extracellular vesicles (EVs). Extracell Vesicles Circ Nucl Acids. 2021;2:80\u2013103. https:\/\/doi.org\/10.20517\/EVCNA.2021.07.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"key":"2117_CR156","doi-asserted-by":"publisher","first-page":"789","DOI":"10.7150\/THNO.18133","volume":"7","author":"P Li","year":"2017","unstructured":"Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics. 2017;7:789. https:\/\/doi.org\/10.7150\/THNO.18133.","journal-title":"Theranostics"},{"key":"2117_CR157","doi-asserted-by":"publisher","unstructured":"Th\u00e9ry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3. https:\/\/doi.org\/10.1002\/0471143030.CB0322S30.","DOI":"10.1002\/0471143030.CB0322S30"},{"key":"2117_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCB.2022.151227","volume":"101","author":"M Clos-Sansalvador","year":"2022","unstructured":"Clos-Sansalvador M, Mongui\u00f3-Tortajada M, Roura S, Franquesa M, Borr\u00e0s FE. Commonly used methods for extracellular vesicles\u2019 enrichment: implications in downstream analyses and use. Eur J Cell Biol. 2022;101:151227. https:\/\/doi.org\/10.1016\/J.EJCB.2022.151227.","journal-title":"Eur J Cell Biol"},{"key":"2117_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS18061190","volume":"18","author":"M Gimona","year":"2017","unstructured":"Gimona M, Pachler K, Laner-Plamberger S, Schallmoser K, Rohde E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int J Mol Sci. 2017;18:1190. https:\/\/doi.org\/10.3390\/IJMS18061190.","journal-title":"Int J Mol Sci"},{"key":"2117_CR160","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1609206","author":"KW Witwer","year":"2019","unstructured":"Witwer KW, Van Balkom BWM, Bruno S, Choo A, Dominici M, Gimona M, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019. https:\/\/doi.org\/10.1080\/20013078.2019.1609206.","journal-title":"J Extracell Vesicles"},{"key":"2117_CR161","doi-asserted-by":"publisher","unstructured":"Tetta C, Camussi G. Challenges and opportunities in translating extracellular vesicles into clinical applications. (n.d.). https:\/\/doi.org\/10.1089\/scd.2025.0051.","DOI":"10.1089\/scd.2025.0051"},{"issue":"3","key":"2117_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0223-5","volume":"51","author":"DE Murphy","year":"2019","unstructured":"Murphy DE, de Jong OG, Brouwer M, Wood MJ, Lavieu G, Schiffelers RM, et al. Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med. 2019;51(3):1\u201312. https:\/\/doi.org\/10.1038\/s12276-019-0223-5.","journal-title":"Exp Mol Med"},{"key":"2117_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/JEV.V4.26316","volume":"4","author":"OPB Wiklander","year":"2015","unstructured":"Wiklander OPB, Nordin JZ, O\u2019Loughlin A, Gustafsson Y, Corso G, M\u00e4ger I, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015;4:1\u201313. https:\/\/doi.org\/10.3402\/JEV.V4.26316.","journal-title":"J Extracell Vesicles"},{"key":"2117_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS17080990","volume":"17","author":"N Verma","year":"2025","unstructured":"Verma N, Arora S, Verma N, Arora S. Navigating the global regulatory landscape for exosome-based therapeutics: challenges, strategies, and future directions. Pharmaceutics. 2025;17:17. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17080990.","journal-title":"Pharmaceutics"},{"key":"2117_CR165","doi-asserted-by":"publisher","unstructured":"Wang CK, Tsai TH, Lee CH. Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. Clin Transl Sci. 2024;17. https:\/\/doi.org\/10.1111\/CTS.13904.","DOI":"10.1111\/CTS.13904"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02117-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02117-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02117-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:21:06Z","timestamp":1776021666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02117-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":165,"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02117-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Author LK is an employee and\/or shareholder of Valo Therapeutics. The other authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}